000303508 001__ 303508
000303508 005__ 20250816200218.0
000303508 0247_ $$2doi$$a10.1093/jnci/djaf222
000303508 0247_ $$2pmid$$apmid:40811636
000303508 0247_ $$2ISSN$$a0027-8874
000303508 0247_ $$2ISSN$$a1460-2105
000303508 0247_ $$2ISSN$$a1475-4029
000303508 037__ $$aDKFZ-2025-01698
000303508 041__ $$aEnglish
000303508 082__ $$a610
000303508 1001_ $$aMajidi, Azam$$b0
000303508 245__ $$aThyroid hormones and epithelial ovarian cancer risk and survival: results from the EPIC study.
000303508 260__ $$aOxford$$bOxford Univ. Press$$c2025
000303508 3367_ $$2DRIVER$$aarticle
000303508 3367_ $$2DataCite$$aOutput Types/Journal article
000303508 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1755266564_8664
000303508 3367_ $$2BibTeX$$aARTICLE
000303508 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000303508 3367_ $$00$$2EndNote$$aJournal Article
000303508 520__ $$aThyroid-stimulating hormone (TSH) and thyroid hormones (free triiodothyronine[fT3] and free thyroxine[fT4]) may influence cancer outcomes, but evidence for ovarian cancer is limited.We conducted a nested case-control study comparing 578 epithelial ovarian cancer (EOC) cases to matched controls within the European Prospective Investigation into Cancer and Nutrition (EPIC). To examine associations between circulating TSH, fT3, and fT4 levels and EOC risk, we estimated risk ratios (RRs) and 95% confidence intervals (CIs) per standard deviation (SD) using conditional logistic regression. Among cases, we evaluated all-cause and EOC-specific survival by pre-diagnostic hormone levels. Hazard ratios (HRs) and 95% CIs were calculated using multivariable Cox regression. We also estimated covariate-adjusted restricted mean survival time (RMST) and survival probabilities at 5 and 10 years.Thyroid hormones were not associated with EOC risk (RR[95%CI] per SD increase: TSH = 0.99[0.87-1.12]), fT3 = 1.12[0.70-1.79], and fT4 = 1.08[0.56-2.07]) levels. However, higher TSH levels were associated with better survival (HR[95%CI] per SD: all-cause death = 0.90[0.82-0.99], EOC-specific = 0.88[0.79-0.97]), while higher fT4 levels were associated with worse survival (all-cause = 1.10[1.00-1.22], EOC-specific = 1.17[1.05-1.30]), but no association for fT3. RMST and survival probabilities showed similar patterns: for TSH , 10-year RMST and survival increased from 5.3 years and 42.2% in Q1 to 6.4 years and 50.7% in (Quartile[Q]4). Conversely, for fT4, 10-year RMST declined from 5.6 years (Q1) to 5.1 years Q4, and survival from 46.3% to 37.8%.TSH and Thyroid hormones might not affect ovarian cancer risk. However, high fT4 and low TSH concentrations may be associated with poorer survival. Further evaluation is suggested in other populations.
000303508 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000303508 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000303508 7001_ $$aRinaldi, Sabina$$b1
000303508 7001_ $$aBiessy, Carine$$b2
000303508 7001_ $$aVozar, Beatrice$$b3
000303508 7001_ $$aTruong, Therese$$b4
000303508 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aTurzanski Fortner, Renée$$b5$$udkfz
000303508 7001_ $$0P:(DE-He78)2d4cac0f4bf270325b98fe07036dc6c6$$aLe Cornet, Charlotte$$b6$$udkfz
000303508 7001_ $$aSchulze, Matthias B$$b7
000303508 7001_ $$aPanico, Camilla$$b8
000303508 7001_ $$aTumino, Rosario$$b9
000303508 7001_ $$aMasala, Giovanna$$b10
000303508 7001_ $$aRicceri, Fulvio$$b11
000303508 7001_ $$aVener, Claudia$$b12
000303508 7001_ $$aSánchez, Maria-José$$b13
000303508 7001_ $$aZamora-Ros, Raúl$$b14
000303508 7001_ $$aCrous-Bou, Marta$$b15
000303508 7001_ $$aColorado-Yohar, Sandra M$$b16
000303508 7001_ $$aGuevara, Marcela$$b17
000303508 7001_ $$aIsraelsson, Pernilla$$b18
000303508 7001_ $$aTravis, Ruth$$b19
000303508 7001_ $$aRiboli, Elio$$b20
000303508 7001_ $$aFournier, Agnès$$b21
000303508 7001_ $$aDossus, Laure$$b22
000303508 773__ $$0PERI:(DE-600)1465951-7$$a10.1093/jnci/djaf222$$gp. djaf222$$pnn$$tJournal of the National Cancer Institute$$vnn$$x0027-8874$$y2025
000303508 909CO $$ooai:inrepo02.dkfz.de:303508$$pVDB
000303508 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000303508 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2d4cac0f4bf270325b98fe07036dc6c6$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000303508 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000303508 9141_ $$y2025
000303508 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-28$$wger
000303508 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJNCI-J NATL CANCER I : 2022$$d2024-12-28
000303508 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-28
000303508 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-28
000303508 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-28
000303508 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-28
000303508 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-28
000303508 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-28
000303508 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-28
000303508 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-28
000303508 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-28
000303508 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-28
000303508 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-28
000303508 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-28
000303508 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJNCI-J NATL CANCER I : 2022$$d2024-12-28
000303508 9201_ $$0I:(DE-He78)C180-20160331$$kC180$$lKrebsepidemiologie$$x0
000303508 980__ $$ajournal
000303508 980__ $$aVDB
000303508 980__ $$aI:(DE-He78)C180-20160331
000303508 980__ $$aUNRESTRICTED